Curacle and Théa Open Innovation have entered an agreement for the development of the potential first oral treatment for diabetic macular edema, according to a press release.
The treatment, CU06-RE, may also be used to treat wet age-related macular degeneration.
“Through this licensing collaboration, Théa and Curacle will provide a new first-in-class treatment with an alternative and non-invasive route of administration and most importantly, convenience for patients,” Théa president Jean-Frédéric Chibret said in the release.
Curacle will receive $6 million up front and is eligible to